The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Desmoplastic small round cell tumor (DSRCT) is an aggressive sarcoma primarily affecting young males.
• Androgen receptor (AR) signaling is implicated in DSRCT progression, but its precise oncogenic mechanisms are unclear.

Purpose of the Study:

• To investigate the role of AR signaling in DSRCT pathogenesis.
• To identify AR-regulated epigenetic programs and potential therapeutic targets in DSRCT.

Main Methods:

• Cell proliferation assays and xenograft studies were used to evaluate the efficacy of AR-targeted therapies.
• Gene expression analysis and chromatin immunoprecipitation sequencing (ChIP-seq) were employed to map AR binding sites and regulatory networks.

Main Results:

• Enzalutamide and AR-ASO significantly inhibited DHT-induced DSRCT cell proliferation and reduced tumor burden in vivo.
• ChIP-seq identified novel AR binding sites in DSRCT, including regions near oncogenic regulators WT1 and FOXF1.
• AR was found to occupy enhancer regions involved in Wnt signaling, neural differentiation, and embryonic development, suggesting a role in aberrant cell lineage commitment.

Conclusions:

• AR signaling is a key driver of DSRCT, promoting tumor growth and potentially influencing cell lineage commitment.
• Targeting AR with existing therapies offers a promising clinical strategy for DSRCT treatment.
• Identification of novel AR binding sites provides new insights into DSRCT-specific AR regulatory networks.